GlassScriptPhysician profile
Benjamin Nels Cantrill
NPI 1467807792
$2,366.58
in general payments reported to CMS, 2019-2025
27 companies · $688 in 2025
The $688 reported for 2025 was more than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $181 · 2021: $404 · 2022: $572 · 2023: $151 · 2024: $370 · 2025: $688.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,210.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,209.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $300.84 | 2019-2023 | Ofev |
| Janssen Pharmaceuticals, INC | $250.00 | 2022 | |
| Glaxosmithkline, LLC. | $245.24 | 2019-2025 | Trelegy Ellipta, Nucala |
| La Jolla Pharmaceutical Company | $214.15 | 2021-2022 | |
| Abbvie INC. | $157.21 | 2022-2024 | |
| Caris Mpi, INC. | $140.18 | 2025 | Mi Cancer Seek |
| Merck Sharp & Dohme LLC | $117.42 | 2022-2025 | Delstrigo, Pifeltro, Dificid |
| Mallinckrodt Hospital Products INC. | $102.72 | 2021 | |
| United Therapeutics Corporation | $92.45 | 2024-2025 | Tyvaso |
| Gilead Sciences, INC. | $87.38 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $76.56 | 2023-2025 | Tezspire, Fasenra, Airsupra |
| Verona Pharma, INC. | $64.42 | 2025 | Ohtuvayre |
| Electromed, INC. | $64.24 | 2025 | Smartvest |
| Ucb, INC. | $56.89 | 2025 | Bimzelx |
| Mylan Specialty L.P. | $46.44 | 2024 | Yupelri |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $40.30 | 2025 | Yupelri |
| Viiv Healthcare Company | $40.06 | 2024 | Dovato, Rukobia |
| Amgen INC. | $39.08 | 2023-2025 | Tavneos, Tezspire |
| Insmed, INC. | $36.94 | 2025 | Arikayce |
| Sandoz INC. | $33.10 | 2024 | Hyrimoz |
| Takeda Pharmaceuticals U.S.A., INC. | $29.87 | 2024 | Glassia |
| Abiomed | $28.26 | 2025 | |
| Pulmonx Corporation | $26.34 | 2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Regeneron Healthcare Solutions, INC. | $21.41 | 2024 | Dupixent |
| Genzyme Corporation | $20.37 | 2023 | |
| Ani Pharmaceuticals, INC. | $18.27 | 2025 | Purified Cortrophin Gel |
| Inspire Medical Systems, INC. | $16.44 | 2025 | Inspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Cantrill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.